Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort
Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx[1] to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort. Results show cutting-edge performance of 95.2% sensitivity and 95.7% specificity for lung nodule characterization that could significantly impact lung cancer screening programs adoption. The large-scale study is based on a cohort of 1,696 patients with a total of 15,608 lung nodules. Further results on a fully automated end-to-end lung cancer screening CADe/CADx including nodule detection and characterizationre expected in Q4, 2021.
Read more